ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer
- World-first stem-cell treatment restores vision in people
- Human stem cell-derived heart cells are safe in monkeys, could treat congenital heart disease
- Markers in iPSC quality control—a new approach to enhance standardization
- Nasal Spray Made From Stem Cells Could Treat Alzheimer’s Disease
- New Stem Cell Data From Space